Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Director | January 26, 2026 | January 27, 2026 |
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | Director | September 23, 2024 | September 25, 2024 |
| CNS Pharmaceuticals, Inc.CNSP · Entity 8048 | Director | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date January 26, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 176,407 |
Reported balance
After 2026-01-26 transaction · row 1
1 source rowRow 1 · 2026-01-26 · Grant · Acquired 37,313 · Balance 176,407 F1: All of the restricted stock will vest on January 26, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the restricted stock will vest on January 26, 2027.
AVENUE THERAPEUTICS, INC.
Report date September 23, 2024 · Filed September 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2034-09-23 | Direct | 30,000 |
Reported balance
After 2024-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-23 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027.
CNS Pharmaceuticals, Inc.
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,100 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Purchase · Acquired 7,100 · Balance 7,100 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CDT Equity Inc.
Report date April 16, 2025 · Filed April 17, 2025
Section 16 reporting ended · disclosed 2025-04-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 165,238 |
Reported balance
After 2025-04-16 transaction · row 1
1 source rowRow 1 · 2025-04-16 · Grant · Acquired 115,194 · Balance 165,238 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 20, 2026 09:03 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | PurchaseCommon Stock | 7,100 | $4.79 | $34,001.90 |
DisclosureSEC source: 0001683168-26-004145 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,100 Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 37,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-003805 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,407 F1 · shares: All of the restricted stock will vest on January 26, 2027. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 17:00 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 1,517 | $0.00 Strike: $12.48 | $0.00 |
DisclosureSEC source: 0001683168-25-008563 · ownership.xml · derivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,517 Underlying: Common Stock · 1,517 shares Expires 2035-11-17 F1 · date: The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date"). F3 · price: Issued in connection with the reporting person's employment with the Company. F2 · derivative.exercise_date: The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 10,738 | $5.86 | $62,878.51 |
DisclosureSEC source: 0001641172-25-018602 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,094 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.78 to $5.92 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 16, 2025 Filed Apr 17, 2025 20:05 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantCommon Stock | 115,194 | $0.87 | $99,999.91 |
DisclosureSEC source: 0001641172-25-005221 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,238 Read SEC document |
| March 30, 2025 Filed Apr 2, 2025 01:04 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantCommon Stock | 46,629 | $0.89 | $41,499.81 |
DisclosureSEC source: 0001641172-25-002234 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,044 F1 · shares: Represents shares issued pursuant to the 2023 Stock Incentive Plan, in lieu of $41,500 accrued in cash retainers under the Issuer's Non-Employee Director Compensation Program. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:37 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 36,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-004751 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,832 F1 · kind: Upon vesting, a portion of the restricted stock may be surrendered to satisfy the reporting person's tax withholding obligation. Any deemed disposition of the withheld shares would be exempt pursuant to Rule 16b-3(e). F2 · shares: All of the restricted stock will vest on January 31, 2026. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 22:06 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantStock Option (Right to Buy) · Derivative | 420,000 | $0.07 Strike: $0.07 | $29,820.00 |
DisclosureSEC source: 0001493152-24-051097 · ownership.xml · derivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,000 Underlying: Common Stock · 420,000 shares Expires 2034-12-18 F1 · security: Represents options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan, which were granted at the conclusion of the Issuer's 2024 annual meeting of stockholders. F2 · derivative.exercise_date: The options will vest on the earlier of (x) the first anniversary of the date of grant, or (y) the date immediately prior to the next annual meeting of the Issuer's stockholders following the date of grant. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 21:30 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantCommon Stock | 266,594 | $0.09 | $24,499.99 |
DisclosureSEC source: 0001493152-24-046991 · ownership.xml · nonDerivative · entry 2 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,594 F2 · shares: Represents shares issued in lieu of $24,500 accrued in cash retainers under the Issuer's Non-Employee Director Compensation Program. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 21:30 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantCommon Stock | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-046991 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · price: The shares are fully vested and were granted under the Issuer's 2023 Stock Incentive Plan. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 16:53 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantEmployee stock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001104659-24-102833 · tm2424771d1_4seq1.xml · derivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-09-23 F1 · derivative.exercise_date: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027. Read SEC document |
| August 26, 2024 Filed Aug 27, 2024 23:08 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 11,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-034054 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,731 F1 · kind: The acquisition was exempt pursuant to Rule 16b-3(d). F2 · shares: This stock grant represents the remainder of the 2024 annual grant to board of directors. This portion of the annual stock grant was withheld until all employees/management were allocated their shares and in order to enable onboarding of two new Board members. All of the restricted stock will vest on August 26, 2025. Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 20:35 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 23,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-026641 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,934 F1 · shares: All of the restricted stock will vest on July 8, 2025. Read SEC document |
| April 26, 2024 Filed Apr 29, 2024 12:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | PurchaseCommon Stock | 7,550 | $3.28 | $24,764.00 |
DisclosureSEC source: 0001493152-24-016852 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,323 Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:50 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantRestricted Stock Units · Derivative | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-24-002283 · ownership.xml · derivative · entry 2 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,815 Underlying: Common Stock · 17,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company common stock. F2 · price: The awards were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. F1 · derivative.expiration_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:50 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 17,500 | Not disclosed Strike: $0.26 | Not disclosed |
DisclosureSEC source: 0001683168-24-002283 · ownership.xml · derivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,315 Underlying: Common Stock · 17,500 shares Expires 2034-04-08 F2 · price: The awards were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 22:20 UTC | CDT Equity Inc. CDT · Entity 1035 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $5.51 Strike: $5.51 | $358,150.00 |
DisclosureSEC source: 0001493152-23-043746 · ownership.xml · derivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-11-30 F1 · security: Represents Options to purchase common stock, granted under the Company's 2023 Stock Incentive Plan. F2 · derivative.exercise_date: The stock options were granted with a ten-year term and vest 33.3% on each of the first three anniversaries of the vesting commencement date, which is September 22, 2023. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 8,330 | $4.91 | $40,923.62 |
DisclosureSEC source: 0001493152-23-034857 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,773 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards. F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $3.8200 to $4.2100 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 18:20 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 45,974 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001683168-23-006678 · ownership.xml · derivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,914 Underlying: Common Stock · 49,474 shares Expires 2033-09-22 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| September 21, 2023 Filed Oct 12, 2023 18:00 UTC Amendment | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 26,315 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001683168-23-007107 · ownership.xml · derivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,815 Underlying: Common Stock · 26,315 shares Expires 2033-09-22 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 16:10 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantEmployee stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001104659-23-078101 · tm2320488d6_4seq1.xml · derivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-06-30 F1 · derivative.exercise_date: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2024; (ii) one-third of the shares subject to the option vest on January 1, 2025; and (iii) one-third of the shares subject to the option vest on January 1, 2026. F2 · derivative.underlying_shares: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 58,689 | $4.62 | $271,143.18 |
DisclosureSEC source: 0001493152-23-021650 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,103 F1 · shares: All of the restricted stock will vest on June 14, 2024. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 16:02 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 3,500 | Not disclosed Strike: $2.40 | Not disclosed |
DisclosureSEC source: 0001683168-23-000026 · ownership.xml · derivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 3,500 shares Expires 2022-12-30 F2 · price: The options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in 36 equal monthly installments succeeding the issuance date, or December 30, 2022, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 20:41 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 13,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-027054 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,414 F1 · shares: All of the restricted stock will vest on September 26, 2023. F2 · balance_after: On July 1, 2022, the issuer effectuated a 1-for-25 reverse stock split. Read SEC document |
| May 25, 2021 Filed May 28, 2021 01:46 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 98,168 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001493152-21-013122 · ownership.xml · derivative · entry 2 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,168 Underlying: Common Stock · 98,168 shares Expires 2031-05-25 F2 · derivative.exercise_date: All of the stock options will vest on November 25, 2021. Read SEC document |
| May 25, 2021 Filed May 28, 2021 01:46 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 77,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-013122 · ownership.xml · nonDerivative · entry 1 Charles Faith L. · CIK 0001853985 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,181 F1 · shares: All of the restricted stock will vest on November 25, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.